


WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009

**AMENDMENTS TO THE CLAIMS:**

Please amend the claims as follows:

Claims 1-79. (Canceled).

80. (Previously Presented) A compound of the formula:



wherein:

the piperazin-1,4-diyI group is optionally substituted;

$J^1$  is independently a covalent bond or  $-C(=O)-$ ;

$J^2$  is independently  $-C(=O)-$  or  $-S(=O)_2-$ ;

wherein:

$Cy$  is independently:

$C_{3-20}$ carbocyclyl,

$C_{3-20}$ heterocyclyl, or

$C_{5-20}$ aryl;

and is optionally substituted;

WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009

Q<sup>1</sup> is independently:

a covalent bond;

C<sub>1-7</sub>alkylene; or

C<sub>1-7</sub>alkylene-X-C<sub>1-7</sub>alkylene, -X-C<sub>1-7</sub>alkylene, or C<sub>1-7</sub>alkylene-X-,

wherein X is -O- or -S-;

and is optionally substituted;

Q<sup>2</sup> is independently:

C<sub>4-8</sub>alkylene;

and is optionally substituted;

and has a backbone length of at least 4 atoms;

or:

Q<sup>2</sup> is independently:

C<sub>5-20</sub>arylene-C<sub>1-7</sub>alkylene;

and is optionally substituted;

and has a backbone length of at least 4 atoms;

or a pharmaceutically acceptable salt thereof,

provided that Cy is not pyridine, pyrimidine, a bicyclic ring containing one nitrogen atom, or a bicyclic ring containing at least one of a sulfur or oxygen.

Claims 81-173. (Canceled)

174. (Previously Presented) A compound according to claim 80, wherein the piperazin-1,4-diyl group is unsubstituted or substituted at one or more the 2-, 3-, 5-, and 6-positions with C<sub>1-4</sub>alkyl.

175. (Previously Presented) A compound according to claim 174, wherein J<sup>1</sup> is a covalent bond and J<sup>2</sup> is -C(=O)-.

176. (Previously Presented) A compound according to claim 174, wherein J<sup>1</sup> is -C(=O)- and J<sup>2</sup> is -C(=O)-.

177. (Previously Presented) A compound according to claim 174, wherein J<sup>1</sup> is a covalent bond and J<sup>2</sup> is -S(=O)<sub>2</sub>-.

178. (Previously Presented) A compound according to claim 174, wherein J<sup>1</sup> is -C(=O)- and J<sup>2</sup> is -S(=O)<sub>2</sub>-.

179. (Previously Presented) A compound according to claim 174, wherein Q<sup>1</sup> is independently a covalent bond.

180. (Previously Presented) A compound according to claim 175, wherein Q<sup>1</sup> is independently a covalent bond.

181. (Previously Presented) A compound according to claim 176, wherein Q<sup>1</sup> is independently a covalent bond.

182. (Previously Presented) A compound according to claim 177, wherein Q<sup>1</sup> is independently a covalent bond.

183. (Previously Presented) A compound according to claim 174, wherein Q<sup>1</sup> is independently C<sub>1-7</sub>alkylene, and is optionally substituted.

184. (Previously Presented) A compound according to claim 175, wherein Q<sup>1</sup> is independently C<sub>1-7</sub>alkylene, and is optionally substituted.

185. (Previously Presented) A compound according to claim 176, wherein Q<sup>1</sup> is independently C<sub>1-7</sub>alkylene, and is optionally substituted.

186. (Previously Presented) A compound according to claim 177, wherein Q<sup>1</sup> is independently C<sub>1-7</sub>alkylene, and is optionally substituted.

187. (Previously Presented) A compound according to claim 174, wherein Q<sup>1</sup> is independently C<sub>1-3</sub>alkylene, and is optionally substituted with one or more groups selected from -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, -NH<sub>2</sub>, -CONH<sub>2</sub>, and =O.

188. (Previously Presented) A compound according to claim 175, wherein Q<sup>1</sup> is independently C<sub>1-3</sub>alkylene, and is optionally substituted with one or more groups selected from -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, -NH<sub>2</sub>, -CONH<sub>2</sub>, and =O.

WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009

189. (Previously Presented) A compound according to claim 176, wherein Q<sup>1</sup> is independently C<sub>1-3</sub>alkylene, and is optionally substituted with one or more groups selected from -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, -NH<sub>2</sub>, -CONH<sub>2</sub>, and =O.

190. (Previously Presented) A compound according to claim 177, wherein Q<sup>1</sup> is independently C<sub>1-3</sub>alkylene, and is optionally substituted with one or more groups selected from -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, -NH<sub>2</sub>, -CONH<sub>2</sub>, and =O.

191. (Previously Presented) A compound according to claim 174, wherein Q<sup>1</sup> is independently C<sub>1-3</sub>alkylene-X-C<sub>1-3</sub>alkylene, -X-C<sub>1-3</sub>alkylene, or C<sub>1-3</sub>alkylene-X- wherein X is -O- or -S- and is optionally substituted with one or more groups selected from -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -OPr, -Ph, -NH<sub>2</sub>, -CONH<sub>2</sub>, and =O.

192. (Previously Presented) A compound according to claim 174, wherein Q<sup>1</sup> is independently C<sub>1-3</sub>alkylene-X-C<sub>1-3</sub>alkylene, -X-C<sub>1-3</sub>alkylene, or C<sub>1-3</sub>alkylene-X- wherein X is -O- or -S-.

193. (Previously Presented) A compound according to claim 174, wherein Q<sup>2</sup> is independently C<sub>4-8</sub>alkylene and is optionally substituted.

194. (Previously Presented) A compound according to claim 174, wherein Q<sup>2</sup> is independently a saturated aliphatic C<sub>4-8</sub>alkylene group.

195. (Previously Presented) A compound according to claim 179, wherein Q<sup>2</sup> is independently a saturated aliphatic C<sub>4-8</sub>alkylene group.

WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009

196. (Previously Presented) A compound according to claim 180, wherein Q<sup>2</sup> is independently a saturated aliphatic C<sub>4-8</sub>alkylene group.

197. (Previously Presented) A compound according to claim 181, wherein Q<sup>2</sup> is independently a saturated aliphatic C<sub>4-8</sub>alkylene group.

198. (Previously Presented) A compound according to claim 187, wherein Q<sup>2</sup> is independently a saturated aliphatic C<sub>4-8</sub>alkylene group.

199. (Previously Presented) A compound according to claim 188, wherein Q<sup>2</sup> is independently a saturated aliphatic C<sub>4-8</sub>alkylene group.

200. (Previously Presented) A compound according to claim 189, wherein Q<sup>2</sup> is independently a saturated aliphatic C<sub>4-8</sub>alkylene group.

201. (Previously Presented) A compound according to claim 192, wherein Q<sup>2</sup> is independently a saturated aliphatic C<sub>4-8</sub>alkylene group.

202. (Previously Presented) A compound according to claim 174, wherein Q<sup>2</sup> is independently selected from -(CH<sub>2</sub>)<sub>5</sub>-, -(CH<sub>2</sub>)<sub>6</sub>-, -(CH<sub>2</sub>)<sub>7</sub>-, and -(CH<sub>2</sub>)<sub>8</sub>-.

203. (Previously Presented) A compound according to claim 174, wherein Q<sup>2</sup> is independently C<sub>5-20</sub>arylene-C<sub>1-7</sub>alkylene and is optionally substituted.

204. (Previously Presented) A compound according to claim 174, wherein Q<sup>2</sup>, is independently C<sub>5-6</sub>arylene-C<sub>1-7</sub>alkylene and is optionally substituted.

WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009


Claim 205. (Canceled)

206. (Previously Presented) A compound according to claim 174, wherein Q<sup>2</sup>, is independently phenylene-methylene, phenylene-ethylene, or phenylene-ethenylene and is optionally substituted.


207. (Previously Presented) A compound according to claim 206, wherein the phenylene linkage is meta.

208. (Previously Presented) A compound according to claim 206, wherein the phenylene linkage is para.


209. (Previously Presented) A compound according to claim 174, wherein Q<sup>2</sup>, is independently:




210. (Previously Presented) A compound according to claim 179, wherein Q<sup>2</sup>, is independently:




211. (Previously Presented) A compound according to claim 182, wherein Q<sup>2</sup>, is independently:



212. (Previously Presented) A compound according to claim 187, wherein Q<sup>2</sup>, is independently:



213. (Previously Presented) A compound according to claim 190, wherein Q<sup>2</sup>, is independently:



214. (Previously Presented) A compound according to claim 174, wherein Q<sup>2</sup> has a backbone of at least 5 atoms.

215. (Previously Presented) A compound according to claim 174, wherein Q<sup>2</sup> has a backbone of at least 6 atoms.

216. (Previously Presented) A compound according to claim 174, wherein Cy is independently  $C_{5-20}$ carboaryl or  $C_{5-20}$ heteroaryl and is optionally substituted.

217. (Previously Presented) A compound according to claim 174, wherein Cy is independently phenyl, furanyl, pyrrolyl, imidazolyl, pyrazinyl, pyridinyl, naphthyl, fluorenlyl, acridinyl, or carbazolyl; and is optionally substituted.

218. (Previously Presented) A compound according to claim 174, wherein Cy is independently phenyl or naphthyl; and is optionally substituted.

219. (Previously Presented) A compound according to claim 174, wherein Cy is independently phenyl and is optionally substituted.

220. (Previously Presented) A compound according to claim 179, wherein Cy is independently phenyl and is optionally substituted.

221. (Previously Presented) A compound according to claim 187, wherein Cy is independently phenyl and is optionally substituted.

222. (Previously Presented) A compound according to claim 194, wherein Cy is independently phenyl and is optionally substituted.

223. (Previously Presented) A compound according to claim 195, wherein Cy is independently phenyl and is optionally substituted.

224. (Previously Presented) A compound according to claim 196, wherein Cy is independently phenyl and is optionally substituted.

225. (Previously Presented) A compound according to claim 197, wherein Cy is independently phenyl and is optionally substituted.

226. (Previously Presented) A compound according to claim 198, wherein Cy is independently phenyl and is optionally substituted.

227. (Previously Presented) A compound according to claim 199, wherein Cy is independently phenyl and is optionally substituted.

228. (Previously Presented) A compound according to claim 200, wherein Cy is independently phenyl and is optionally substituted.

229. (Previously Presented) A compound according to claim 201, wherein Cy is independently phenyl and is optionally substituted.

230. (Previously Presented) A compound according to claim 209, wherein Cy is independently phenyl and is optionally substituted.

231. (Previously Presented) A compound according to claim 210, wherein Cy is independently phenyl and is optionally substituted.

232. (Previously Presented) A compound according to claim 211, wherein Cy is independently phenyl and is optionally substituted.

233. (Previously Presented) A compound according to claim 212, wherein Cy is independently phenyl and is optionally substituted.

234. (Previously Presented) A compound according to claim 213, wherein Cy is independently phenyl and is optionally substituted.

235. (Previously Presented) A compound according to claim 174, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br, -OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph, -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

236. (Previously Presented) A compound according to claim 179, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph,

WATKINS et al

Appl. No. 10/509,732

Atty Ref.: 620-334

Amendment After Final Rejection

May 8, 2009

-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,  
-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

237. (Previously Presented) A compound according to claim 180, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu),  
-C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH,  
-C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>,  
-(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph,  
-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,  
-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

238. (Previously Presented) A compound according to claim 181, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br, -OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph, -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

239. (Previously Presented) A compound according to claim 182, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,

WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009

-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

240. (Previously Presented) A compound according to claim 187, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br, -OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph, -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

241. (Previously Presented) A compound according to claim 188, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH,

WATKINS et al

Appl. No. 10/509,732

Atty Ref.: 620-334

Amendment After Final Rejection

May 8, 2009

-C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>,  
-(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph,  
-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,  
-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

242. (Previously Presented) A compound according to claim 189, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu),  
-C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH,  
-C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>,  
-(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph,  
-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,  
-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

243. (Previously Presented) A compound according to claim 190, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br, -OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph, -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

244. (Previously Presented) A compound according to claim 195, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,

WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009

-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

245. (Previously Presented) A compound according to claim 196, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br, -OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph, -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

246. (Previously Presented) A compound according to claim 197, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH,

WATKINS et al

Appl. No. 10/509,732

Atty Ref.: 620-334

Amendment After Final Rejection

May 8, 2009

-C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>,  
-(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph,  
-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,  
-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

247. (Previously Presented) A compound according to claim 198, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu),  
-C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH,  
-C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>,  
-(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph,  
-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,  
-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

248. (Previously Presented) A compound according to claim 199, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br, -OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph, -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

249. (Previously Presented) A compound according to claim 200, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,

WATKINS et al

Appl. No. 10/509,732

Atty Ref.: 620-334

Amendment After Final Rejection

May 8, 2009

-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

250. (Previously Presented) A compound according to claim 210, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu),  
-C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH,  
-C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>,  
-(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph,  
-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,  
-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

251. (Previously Presented) A compound according to claim 211, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu),  
-C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH,

WATKINS et al

Appl. No. 10/509,732

Atty Ref.: 620-334

Amendment After Final Rejection

May 8, 2009





-C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>,  
-(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph,  
-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,  
-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

252. (Previously Presented) A compound according to claim 212, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu),  
-C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH,  
-C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>,  
-(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph,  
-F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>,  
-OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br,  
-OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH,  
-CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph,  
-Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph,  
-SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.


253. (Previously Presented) A compound according to claim 213, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)OEt, -C(=O)O(Pr), -C(=O)O(iPr), -C(=O)O(nBu), -C(=O)O(sBu), -C(=O)O(iBu), -C(=O)O(tBu), -C(=O)O(nPe), -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OH, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OMe, -C(=O)OCH<sub>2</sub>CH<sub>2</sub>OEt, -(C=O)NH<sub>2</sub>, -(C=O)NMe<sub>2</sub>, -(C=O)NEt<sub>2</sub>, -(C=O)N(iPr)<sub>2</sub>, -(C=O)N(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub>, -(C=O)Me, -(C=O)Et, -(C=O)-cHex, -(C=O)Ph, -F, -Cl, -Br, -I, -OH, -OMe, -OEt, -O(iPr), -O(tBu), -OPh, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OCH<sub>2</sub>CH<sub>2</sub>OMe, -OCH<sub>2</sub>CH<sub>2</sub>OEt, -OCH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -OCH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -OPh, -OPh-Me, -OPh-OH, -OPh-OMe, -OPh-F, -OPh-Cl, -OPh-Br, -OPh-I, -Me, -Et, -nPr, -iPr, -nBu, -iBu, -sBu, -tBu, -nPe, -CF<sub>3</sub>, -CH<sub>2</sub>CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OMe, -CH<sub>2</sub>CH<sub>2</sub>OEt, -CH<sub>2</sub>CH<sub>2</sub>NH<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -CH<sub>2</sub>CH<sub>2</sub>N(iPr)<sub>2</sub>, -CH<sub>2</sub>-Ph, -Ph, -Ph-Me, -Ph-OH, -Ph-OMe, -Ph-F, -Ph-Cl, -Ph-Br, -Ph-I, -SO<sub>2</sub>Me, -SO<sub>2</sub>Et, -SO<sub>2</sub>Ph, -SO<sub>2</sub>NH<sub>2</sub>, -SO<sub>2</sub>NMe<sub>2</sub>, -SO<sub>2</sub>NEt<sub>2</sub>, -NMe<sub>2</sub>, -NEt<sub>2</sub>, morpholino, -NO<sub>2</sub>, and -CN.

254. (Previously Presented) A compound according to claim 174, wherein Cy is independently phenyl and is optionally substituted with one or more groups selected from -C(=O)OMe, -C(=O)O(Pr), -C(=O)NHMe, -C(=O)Et, -C(=O)Ph, -OCH<sub>2</sub>CH<sub>2</sub>OH, -OMe, -OPh, -nPr, -iPr, -CF<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>NMe<sub>2</sub>, -Ph, -Ph-F, -Ph-Cl, -SO<sub>2</sub>Me, -SO<sub>2</sub>Me<sub>2</sub>, -NMe<sub>2</sub>, -F, -Cl, -Me, -Et, -OMe, -OEt, -CH<sub>2</sub>-Ph, and -O-CH<sub>2</sub>-Ph.


255. (Previously Presented) A compound according to claim 80, selected from the following compounds, and pharmaceutically acceptable salts thereof:




WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009




,




,



,








,








,

WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009



WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009




WATKINS et al

Appl. No. 10/509,732


Atty Ref.: 620-334

Amendment After Final Rejection


May 8, 2009




,




,




,








,




256. (Previously Presented) A compound according to claim 80, selected from the following compounds, and pharmaceutically acceptable salts thereof:




WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009






,




, and




.

257. (Previously Presented) A compound according to claim 80, selected from the following compounds, and pharmaceutically acceptable salts thereof:










,









,

WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009



WATKINS et al  
Appl. No. 10/509,732  
Atty Ref.: 620-334  
Amendment After Final Rejection  
May 8, 2009








WATKINS et al

Appl. No. 10/509,732






Atty Ref.: 620-334

Amendment After Final Rejection

May 8, 2009



258. (Previously Presented) A compound according to claim 80, selected from the following compounds, and pharmaceutically acceptable salts thereof:




WATKINS et al

Appl. No. 10/509,732


Atty Ref.: 620-334

Amendment After Final Rejection


May 8, 2009




,




,



,



,



,




WATKINS et al

Appl. No. 10/509,732

Atty Ref.: 620-334

Amendment After Final Rejection

May 8, 2009



259. (Previously Presented) A composition comprising a compound according to claim 80 and a pharmaceutically acceptable carrier.